NCT02764125已完成2 期
Efficacy and Safety of ODM-104 Compared to a Standard Combination (Stalevo®); a Randomized Double-blind, Crossover Proof-of-concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 84
- 试验地点
- 4
- 主要终点
- Duration of daily OFF-time (measured by Hauser ON/OFF-diary)
研究概览
简要总结
This will be a randomised, crossover, double-blind, double-dummy, active-controlled, multicentre, phase II proof-of-concept study in Parkinson's Disease (PD) patients with end-of-dose wearing-off (motor fluctuations).
详细描述
This will be a randomised, crossover, double-blind, double-dummy, active-controlled, multicentre, phase II proof-of-concept study in PD patients with end-of-dose wearing-off (motor fluctuations).
In a 2-period crossover design the subjects will receive ODM-104/levodopa/ carbidopa or Stalevo during the different study periods in a randomised order. There will be a screening period, 2 treatment periods and a post-treatment period, altogether 7 scheduled visits: a screening visit, a baseline visit, 4 visits during the treatment periods (i.e. 2 visits/each period), and an end-of-study visit. Unscheduled visits may be performed during the first 2 weeks of each treatment period, if there is a need to adjust the levodopa strength. The total study duration will be 10-15 weeks for each subject.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent (IC) obtained.
- •Male or female patients with idiopathic PD according to the UK brain bank criteria with end-of-dose wearing-off (motor fluctuations).
- •Hoehn and Yahr stage 2-4 performed during the ON-state.
- •At least 2 hours of OFF-time on each day (measured by the ON/OFF diary) on 3 consecutive days at the end of the screening period just before the baseline visit (visit 1).
- •Treatment with 4-8 daily doses of levodopa/AADC inhibitor, either combined with entacapone (levodopa/AADC inhibitor combined with Comtess/Comtan or as Stalevo) or without entacapone, with a total daily levodopa dose from > 400 mg to ≤ 1200 mg with entacapone, or from > 400 mg to ≤ 1400 mg without entacapone. One evening dose of controlled release formulation, 1 morning dose of soluble levodopa/AADC inhibitor, or both, as needed are allowed.
- •Unchanged levodopa/AADC inhibitor with or without entacapone, and other antiparkinsonian medication (dopamine agonists, monoamine oxidase [MAO] B inhibitor, amantadine and/or anticholinergics with doses recommended by the manufacturer), if any, for at least 4 weeks before the screening visit.
- •Age of 30 years or above.
排除标准
- •Secondary or atypical Parkinsonism.
- •Current use of tolcapone or opicapone (within 4 weeks before the screening visit).
- •Previous tolerability problems with entacapone, tolcapone or opicapone.
- •Concomitant treatment with apomorphine, MAO-A inhibitors or non-selective MAO inhibitors (within 4 weeks before the screening visit).
- •Concomitant treatment with drugs having antidopaminergic action including alpha-methyldopa, reserpine and antipsychotic drugs (also D2 receptor blocking antiemetics except domperidone). As an exception to prohibit use of antipsychotic drugs, 1 evening dose of an atypical antipsychotic is allowed.
- •Use of concomitant medicine which is predominantly metabolised by CYP3A4 and which has a narrow therapeutic window such as ergot alkaloids, carbamazepine, cyclosporin, macrolides (sirolimus and tacrolimus), quinidine or fentanyl.
- •Current use of warfarin (within 4 weeks before the screening visit).
- •Inability to refrain from use of any iron preparations during the study.
- •Disabling dyskinesias.
- •Problematic hallucinations within 3 months before the screening visit.
- •Symptomatic orthostatic hypotension.
- •Current dementia (Mini Mental State Examination [MMSE] score < 26).
- •Problematic impulse control disorders (ICDs), such as pathological gambling, hypersexuality or compulsive shopping within 6 months before the screening visit.
- •History of neuroleptic malignant syndrome (NMS), non-traumatic rhabdomyolysis, or both.
- •Any neurosurgical intervention for the treatment of PD, including deep brain stimulation (DBS).
- •Narrow-angle glaucoma or pheochromocytoma.
- •Any active malignant cancer.
- •Clinically significant cardiovascular (e.g. ischaemic heart disease, ventricular or supraventricular arrhythmias), pulmonary, GI (e.g. inflammatory bowel disease), hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator would interfere with the interpretation of the study results or constitute a health risk for the subject if he/she takes part into the study.
- •Alanine aminotransferase or aspartate aminotransferase > 1.25 x upper limit of normal (ULN) at screening.
- •Any other abnormal value of laboratory, vital signs or ECG (such as QTcF prolongation ≥ 450 ms) that may in the opinion of the investigator interfere with the interpretation of the study results or cause health risk for the subject if he/she takes part into the study.
- •Female patients of childbearing potential (i.e. menstruating or less than 2 years postmenopausal).
- •Patients with pre-planned surgery requiring hospitalisation during the study.
- •Known hypersensitivity to active substances or to any of the excipients of the study treatments.
- •Blood donation or loss of significant amount of blood within 60 days before screening visit.
- •Participation in a drug study within 60 days before the first treatment period.
- •Any other condition that in the opinion of the investigator would interfere with the interpretation of the study results or constitute a health risk for the subject if he/she takes part into the study.
- •Failure to demonstrate acceptable/appropriate use of the ON/OFF diary despite adequate training during the screening visit.
研究组 & 干预措施
Stalevo
Active Comparator
levodopa/carbidopa/entacapone
干预措施: Stalevo (Drug)
levodopa MR
Experimental
Levodopa MR/carbidopa/ODM-104
干预措施: levodopa MR (Drug)
结局指标
主要结局
Duration of daily OFF-time (measured by Hauser ON/OFF-diary)
时间窗: 3 consecutive days in the end of both periods compared to 3 consecutive days prior the baseline visit.
OFF-time (time when the patient does not experience a positive response to medication between the study drug intake) measured from the Hauser ON/OFF-diary that patient has filled in (24 hour clock) for 3 days prior to baseline visit and at the end of both treatment periods.
次要结局
- To show adequate Parkinson's Disease symptom control with the new treatment(two 4 weeks study periods)
- Switching patients from their regular levodopa treatment to planned new treatment.(two 4 weeks study periods)
- Determination of sample size(two 4 weeks study periods)
研究者
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.Parkinson’s disease (PD) patients with end-of-dose wearing-off (motor fluctuations)EUCTR2015-004507-23-HUOrion Corporation80
进行中（未招募）
1 期
Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.EUCTR2015-004507-23-FIOrion Corporation80
进行中（未招募）
1 期
Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.Parkinson’s disease (PD) patients with end-of-dose wearing-off (motor fluctuations)EUCTR2015-004507-23-DEOrion Corporation80
进行中（未招募）
1 期
Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.Parkinson's disease (PD) patients with end-of-dose wearing-off (motor fluctuations)EUCTR2015-004507-23-LVOrion Corporation60
进行中（未招募）
不适用
Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®) in patients with Parkinson’s disease.Parkinson's diseaseMedDRA version: 14.1Level: LLTClassification code 10013113Term: Disease Parkinson'sSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-022200-46-FIOrion Corporation100